A new study, presented at the 2016 Alzheimer’s Association International Conference, suggested that treating people with Alzheimer’s disease may increase survival and reduce cost, even though the treatment does not change the underlying course of the disease.
A new study, presented at the 2016 Alzheimer’s Association International Conference, suggested that treating people with Alzheimer’s disease may increase survival and reduce cost, even though the treatment does not change the underlying course of the disease.
The researchers followed 6553 individuals with Alzheimer’s—identified through Medicare fee-for-service claims—and followed the participants until death, disenrollment, or the end of the study period. Patients were assigned into either the treated or non-treated group based on whether they were prescribed an existing Alzheimer’s drug after their diagnosis.
“The new results support that early Alzheimer’s treatment—even with today’s first-generation therapies—has significant potential to benefit the person with the disease and the economy,” Maria C. Carrillo, PhD, chief science officer of the Alzheimer’s Association, said in a statement.
Patients who had never been treated had a death rate that was almost twice as high as the people who received treatment. In addition, non-treated patients had more comorbidities and were generally older. Plus, expenditures were higher for the people who did not receive a treatment.
In the first month following an Alzheimer’s diagnosis, average healthcare costs more than tripled for all participants in the study. However, those receiving a treatment had slightly lower costs ($5535) in the month of diagnosis compared with those who did not receive a treatment ($6711). According to the researchers, inpatient care was the biggest contributor to the cost increase and accounted for 30% of the total expenditures for both the treated and non-treated groups.
While patients receiving a treatment for dementia had an increase in pharmacy costs during the follow-up period, their total health expenditure was less than individuals who did not take medications approved for treating dementia ($2207 vs $2349 per patient per month).
“The arguments for early treatment are myriad, but this study shows greater survival and less all-cause healthcare costs among those receiving treatment for dementia,” said Christopher M. Black, MPH, from Merck Research Laboratories. “These results indicate that choosing not to treat, or even a delay in starting treatment, may lead to less favorable results. Early diagnosis and time to treatment should be a priority for policy makers, physicians, and the public.”
Another study presented at the conference found that more than 369,000 hospital admissions of people with Alzheimer’s in 2013 in the United States were potentially avoidable. Researchers used Medicare claims data and the associated expenditures for more than 2.7 million people diagnosed with Alzheimer’s or other dementia. Potentially avoidable hospitalization rates were examined for acute and chronic conditions.
The researchers found that 10% of people studied had at least potentially avoidable hospitalization. The 369,165 potentially avoidable hospitalizations accounted for $2.58 billion in Medicare expenditures. In addition, late-stage dementia and multiple chronic comorbidities were significantly associated with potentially avoidable hospitalizations.
“Case management programs for people with Alzheimer’s and other dementias should involve strategies to reduce avoidable hospitalizations in order to improve patient outcomes and lower costs,” said first author Pei-Jung Lin, PhD, from the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center.
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Study Highlights BMP7 as a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More